BIOTON S.A. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.485 PLN | -0.43% |
|
-0.43% | -2.38% |
| Mar. 28 | BIOTON S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | BIOTON S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
| Sales 2022 | 233M 57.31M | Sales 2023 | 182M 44.65M | Capitalization | 307M 75.35M |
|---|---|---|---|---|---|
| Net income 2022 | 1M 246K | Net income 2023 | 2M 492K | EV / Sales 2022 | 1.53 x |
| Net Debt 2022 | 67.05M 16.48M | Net Debt 2023 | 65.21M 16.03M | EV / Sales 2023 | 2.05 x |
| P/E ratio 2022 |
204
x | P/E ratio 2023 |
135
x | Employees | 357 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 40.31% |
More Fundamentals
* Assessed data
More news
More press releases
| Current month | -1.96% | ||
| 1 month | -2.64% | ||
| 3 months | -0.43% | ||
| 6 months | -7.41% | ||
| Current year | -1.96% |
1 week
3.48
3.55
1 month
3.303.60
Current year
3.303.78
1 year
3.304.10
3 years
3.266.11
5 years
2.007.82
10 years
2.0017.35
| Managers | Title | Age | Since |
|---|---|---|---|
Jeremy Launders
CEO | Chief Executive Officer | - | 20-10-29 |
Anna Grabowska
DFI | Director of Finance/CFO | - | 18-08-31 |
Jolanta Lis
ADM | Chief Administrative Officer | - | 16-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tomasz Siembida
BRD | Director/Board Member | - | 21-12-31 |
Ju Bo Liu
BRD | Director/Board Member | 51 | 21-12-31 |
Nicola Cadei
BRD | Director/Board Member | - | 19-12-02 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 117 M€ | -1.38% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 3.485 | -0.43% | 7 686 |
| 24-04-18 | 3.5 | 0.00% | 35,814 |
| 24-04-17 | 3.5 | +0.14% | 8,911 |
| 24-04-16 | 3.495 | -0.71% | 19,093 |
| 24-04-15 | 3.52 | +0.57% | 24,341 |
Delayed Quote Warsaw S.E., April 19, 2024 at 05:29 am EDT
More quotes
Bioton SA is a Poland-based company active in the pharmaceutical sector. The Company is engaged in research, development and wholesale trade of pharmaceutical and biotechnological products. The Company's portfolio consists of oral hypoglycemic drugs (metformin and glimepride) as well as recombinant human insulin in pharmaceutical substance form and for injections. Additionally, the Company provides advertising services. As of December 31, 2011, the Company formed a capital group and operated through its subsidiaries, including BIOTON TRADE Sp. z o.o., Mindar Holdings Ltd, Germonta Holdings Ltd, Tricel SA, SciGen Ltd and BioPartners Holdings AG, among others. On June 12, 2014, it sold a 50% stake in Copernicus Sp. z o.o.
Calendar
2024-04-29
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -1.96% | 73.99M | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -1.34% | 21.66B | |
| -18.35% | 20.77B | |
| -8.58% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- BIO Stock
